Inhibitor Therapeutics公布伊曲康唑治疗戈林综合征项目的临床、制剂及知识产权进展

美股速递
Apr 01

Inhibitor Therapeutics Inc. (简称INTI) 近日宣布,针对其用于治疗戈林综合征的伊曲康唑项目,已取得一系列重要进展。此次更新主要涵盖临床研究、制剂开发及知识产权保护三大关键领域,标志着该项目在研发进程中迈出了坚实的一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10